Introduction {#s1}
============

The prevalence of type 2 diabetes has been rising steadily around the world ([@c7]). Apart from traditional diabetes risk factors, a recent line of research has focused on the role of environmental toxicants and suggests that exposure to endocrine-disrupting chemicals may play a role in the incidence of diabetes ([@c18]). In particular, bisphenol A (BPA) has been suspected as a potential contributor to the etiology of metabolic diseases such as type 2 diabetes ([@c21]). BPA is a chemical commonly used in the production of polycarbonate plastic and epoxy resins and is found in numerous consumer products such as food/beverage containers and thermal cash register receipts. BPA is structurally similar to the natural estrogen $17\beta\text{-estradiol}$ and, consequently, a known xenoestrogen. Experimental data from *in vitro* and *in vivo* studies have suggested plausible mechanisms implicating BPA in the development of type 2 diabetes through insulin resistance, pancreatic beta-cell dysfunction, adipogenesis, inflammation, oxidative stress, dysregulation of glucose metabolism, and disruption of thyroid hormone balance ([@c1]).

The growing concern over BPA and its use restriction in some countries have prompted the replacement of BPA with alternative compounds, including BPA structural analogs such as bisphenol S (BPS), used in some BPA-free products such as thermal receipts and epoxy resins and in the coatings of food and drink cans ([@c8]). A study conducted in a convenience population sample in the United States between 2000 and 2014 suggested that exposure to BPS was increasing while exposure to BPA was declining, even though BPS concentrations measured in urine were still lower than those of BPA ([@c35]). Recently, a systematic review concluded that BPS has endocrine-disrupting effects similar to those of BPA ([@c23]).

Evidence from cross-sectional epidemiological studies suggests that individuals with diabetes are more likely to have higher urinary bisphenols concentrations ([@c9]; [@c21]). However, whether exposure to bisphenols is a risk factor for developing type 2 diabetes is still unclear due to the absence (for BPS) or lack (for BPA) of prospective data to ascertain the nature of the relationship. Existing longitudinal studies on BPA and diabetes reported no significant association ([@c25]) or they reported significant positive associations only in specific subgroups based on sex and age ([@c27]) or on a diabetes genetic risk score ([@c5]). Other limitations in the existing literature include self-reported diabetes diagnosis, lack of adjustment for important confounders such as dietary intake, as well as a single urinary BPA measurement per participant, which is a concern due to the short half-life of BPA in humans ([@c21]).

The aim of the present study was to investigate the prospective association between repeated measures of urinary BPA and BPS and the risk of developing type 2 diabetes over 9 y in the French cohort study Data from an Epidemiological Study on the Insulin Resistance Syndrome (D.E.S.I.R.).

Methods {#s2}
=======

Source Population {#s2.1}
-----------------

D.E.S.I.R. is a prospective, population-based cohort study that aims to clarify the development of the insulin resistance syndrome and type 2 diabetes ([@c2]). Between 1994 and 1996, this study included 5,212 men and women 30--65 years of age, enrolled from volunteers offered free periodic health examinations by the French Health Insurance System in 10 health examination centers in central-western France. Participants were clinically and biologically evaluated at inclusion and then at 3-, 6-, and 9-y visits. At each visit, urine and blood samples were collected in a standardized way, the morning after participants had fasted for at least 12 h. Detailed information about the follow-up has been previously published ([@c2]). The study protocol was approved by French ethics committees \[Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale (CCPPRB) de Bicêtre, Hôpital de Bicêtre, Paris, France\] and written informed consent was obtained from all participants.

Study Population {#s2.2}
----------------

We conducted a case--cohort study nested in the D.E.S.I.R. cohort. All participants with a baseline urine sample and blood glucose and body mass index (BMI) data at baseline and 9-y visits were eligible for this study ($n = 3,409$). We randomly selected 600 participants from all the eligible participants and which we refer to as the subcohort. This group corresponds to a subcohort sampling fraction of 11.5%, which is in line with other case--cohort studies ([@c24]). Incident diabetes was defined by treatment with glucose-lowering agents or a fasting plasma glucose of $\geq 7.0\text{ \ mmol}/L$ or glycated hemoglobin ($\left. \text{HbA}_{1c} \right)\text{ \ of} \geq 6.5\%$ at any of the three 3-yearly health examinations after inclusion. After excluding participants with prevalent diabetes or uncertain status at baseline, the final study population included 584 subcohort members and 201 incident cases of diabetes, 30 of whom were in the subcohort. Among the 201 incident cases, 82 were diagnosed with diabetes between baseline and year 3, 50 between year 3 and year 6, and 69 between year 6 and year 9. In total, 47 participants were diagnosed with type 2 diabetes based on treatment, and 154 were diagnosed based on fasting plasma glucose or $\text{HbA}1_{c}$ testing. The selection of participants is described in detail in [Figure 1](#f1){ref-type="fig"}.

![Flow chart of the case--cohort study nested in the French prospective cohort study D.E.S.I.R. BMI, body mass index; D.E.S.I.R., Data from an Epidemiological Study on the Insulin Resistance Syndrome; FPG, fasting plasma glucose; $\text{HbA}_{1c}$, glycated hemoglobin; T2D, type 2 diabetes.](ehp-127-107013-g001){#f1}

Assessment of Urinary BPA-Glucuronide and BPS-Glucuronide {#s2.3}
---------------------------------------------------------

We measured BPA-glucuronide (BPA-G) and BPS-glucuronide (BPS-G), major BPA and BPS urinary metabolites, in spot urine samples obtained at baseline and at the second (3-y) study examination \[median 3.0 y after baseline, interquartile range (IQR): 2.8, 3.1 y\]. All samples were stored at $- 80{^\circ}C$. BPA and BPS exposure can be assayed from stored frozen urine ([@c19]). Samples ($100\,\mu L$) were analyzed as dansyl chloride derivatives using labeled BPA-G and BPS-G as internal standards. Liquid chromatography--mass spectrometry analyses were carried out on an Acquity U-HPLC device \[Waters Cortecs C18 U-HPLC column ($2.1 \times 100\,{mm}$; $1.6\,\mu m$) with an acidified water/acetonitrile gradient elution ($0.3\,{mL}/\text{min}$, 40°C)\] coupled to a Xevo-TQ mass spectrometer (Waters) using positive electrospray ionization and multiple reaction monitoring (MRM) mode. The method was validated according to guidelines of the FDA ([@c10]), from 0.5 to $100\text{ \ ng}/{mL}$, using a linear model weighted by $1/X²$ ($X = \text{concentration}$). The limits of detection (LOD) for both BPA-G and BPS-G were validated at $0.3\text{ \ ng}/{mL}$.

Within- and between-day precisions were calculated on six replicates of quality control points (QC) at three concentration levels (1.5, 7.5, and $75\text{ \ ng}/{mL}$) on 3 d. Within- and between-day precisions \[expressed by coefficient of variation (CV)\] were lower than 6% and 14% for BPA-G and 16% and 17% for BPS-G, respectively. The accuracy varied from 92% to 101% for BPA-G and from 85% to 91% for BPS-G. Recoveries, evaluated with three human urine samples spiked with BPA-G and BPS-G at 1.5 and $7.5\text{ \ ng}/{mL}$, were 88% and 99% for BPA-G and BPS-G, respectively. The limits of quantification (LOQs) were validated at $0.5\text{ \ ng}/{mL}$ with a precision less than 11% and 13% and accuracy of 94% and 105% for BPA-G and BPS-G, respectively. Stability of the dansyl chloride labeling was evaluated with the spiked human urine samples over 24 h. Labeled bisphenol-glucuronides were stable over 12 h with a variation between nominal and observed concentration less than 14%.

Health Outcomes and Covariates {#s2.4}
------------------------------

Blood samples were analyzed for metabolic markers including glucose and $\text{HbA}1_{c}$, and urine samples were analyzed for creatinine, using techniques previously described ([@c2]). Weight and height were measured in lightly clad participants, by trained personnel following a standardized protocol. Blood pressure was measured in duplicate using a mercury sphygmomanometer with the participant in a supine position, and mean values were used for analyses. Information on familial and personal history of diabetes and treatment for diabetes and hypertension was collected during an interview with a physician. A self-administered questionnaire provided data on education level, employment, smoking status, diet, and degree of physical activity. Participants were asked if they currently smoked or have been regular smokers in their lifetime and were categorized as nonsmokers, former smokers, or current smokers. Physical activity was categorized as sedentary, moderately active, or active based on the frequency of participation in active sporting activities (never, $< 1$ time a week, 1--2 times a week, $> 2$ times a week) and the intensity of usual physical activity at home and at work (low, moderate, important, intensive). The dietary intake (in kilocalories per day) was calculated using the New Alimentary Self Questionnaire (NAQA) food consumption questionnaire ([@c12]) describing usual food consumption, based on the composition of breakfast and the frequency of consumption of meat, fish, fried foods, butter, cheese, dairy products, bread, sugary desserts, sugar, soft drinks, and alcoholic beverages (wine, beer, cider, aperitif, digestive).

Statistical Analysis {#s2.5}
--------------------

At both time points of exposure assessment, urinary BPA-G concentrations below the LOD were assigned the value of LOD divided by 2. BPA-G concentrations were categorized into four groups based on the 25th, 50th, and 75th percentiles of the distribution of pooled BPA-G concentrations at both time points in subcohort members. Due to a low detection rate of BPS-G, exposure to BPS was studied as a binary variable, as either detectable (BPS-G concentration $\geq \text{LOD}$) or not.

As a way to reduce misclassification bias, we summarized exposure of participants by deriving BPA exposure and BPS detection from data from the two spot urine samples. BPA average exposure was defined as the mean of urinary BPA-G concentrations measured at baseline and year 3; BPS detection was defined as a binary variable, as either BPS-G detected at baseline and/or year 3 or BPS-G detected at none of the visits.

Within-person repeatability of BPA-G concentrations in spot urine samples collected 3 y apart was assessed using Spearman's rank correlation coefficient ($\rho$) and creatinine-adjusted intraclass correlation coefficients (ICCs) estimated using one-way random-effect models, with BPA-G concentrations divided by the urinary creatinine concentration in the same sample to account for urine dilution. McNemar's test and Cohen's kappa ($\kappa$) assessed the within-person stability of BPS detection categories over the two time points. At both time points, associations between detection of BPA-G and BPS-G were assessed using the chi-square test and Cohen's kappa ($\kappa$).

First, we investigated the association between BPA and BPS exposure at baseline and diabetes incidence between baseline and year 9, after excluding prevalent cases at baseline. Second, we investigated the association between BPA and BPS exposure at year 3 and diabetes incidence between year 3 and year 9, after excluding prevalent cases at baseline and year 3 (see Figure S1). Last, we investigated BPA average exposure and BPS detection at least at one of the time points in relation with diabetes incidence between year 3 and year 9. We performed single-exposure models as well as models including both BPA and BPS exposures.

Multivariable Cox regression models adapted to the case--cohort design using the Prentice method ([@c3]) were used to estimate adjusted hazard ratios (HRs) of incident diabetes with their 95% confidence intervals (CIs). Individual observations were censored on the approximate date of diagnosis for cases, defined as the midpoint between the last visit without diabetes and the first visit with diabetes.

The proportional-hazards assumption was checked using Schoenfeld residuals. We used Cox models stratified by smoking status (never, former, current) because this variable did not satisfy the proportional-hazards assumption ($p < 0.05$). Multivariable models with age as the timescale were adjusted for sex and the following variables from baseline (when examining diabetes incidence between baseline and year 9) or from year-3 (when examining diabetes incidence between year 3 and year 9): education level ($< 12$, $\geq 12\, y$ of education), employment (no, yes), marital status defined as married or living with a partner (no, yes), physical activity (sedentary, moderately active, active), caloric intake (in tertiles), family history of diabetes (no, yes), hypertension defined as systolic blood pressure $\geq 140\text{ \ mmHg}$ or diastolic blood pressure $\geq 90\text{ \ mmHg}$ or ongoing blood pressure-lowering treatment (no, yes), and BMI (continuous). All multivariable models were also adjusted for urinary creatinine levels, measured at the same time point as exposure assessment to account for urine dilution. Models estimating associations with average BPA concentration and BPS detection at least at one of the time points were adjusted for average urine creatinine. We included exposure variables (unadjusted for creatinine) in the analysis, with urinary creatinine concentration added as a separate independent variable so that urinary bisphenol concentration was appropriately adjusted for urinary creatinine and the statistical significance of other variables in the model was independent of the effects of creatinine concentration ([@c4]). Effect--measure modification by sex was investigated by testing multiplicative interaction terms. For BPA, we modeled three product interaction terms for the four categories of exposure, and the interaction *p*-values were derived using Wald tests.

In addition to the analyses described previously, and in order to better understand the shape of the relationship observed between groups of BPA exposure at year 3 and incidence of type 2 diabetes, we modeled the relationship between log-transformed BPA-G and the risk of type 2 diabetes using restricted cubic splines analysis after excluding participants with the highest 5% of BPA-G levels to minimize the potential impact of outliers. We performed the spline analysis with three knots placed at the 10th, 50th, and 90th percentiles of the log-transformed BPA-G concentrations distribution. The multivariable Cox regression model was adjusted for the same covariates as previously described. A test for nonlinearity was conducted by testing that the regression coefficient of the second spline variable equaled 0.

The analyses were performed in Stata/SE (version 13.1; StataCorp), using the STCASCOH procedure to build the data set suitable for case--cohort analysis and the MKSPLINE and XLBC procedures for the restricted cubic spline analysis. We followed the recommendations for reporting case--cohort studies as given by Sharp et al. ([@c24]).

Results {#s3}
=======

Study Population {#s3.1}
----------------

Baseline characteristics of subcohort members and incident diabetes cases are summarized in [Table 1](#t1){ref-type="table"}. The median age at inclusion was 47 (IQR: 39, 57) y in the subcohort, and 53% were women. Sociodemographic characteristics (sex, age, education level) of individuals from the subcohort did not substantially differ from those of other participants included in the D.E.S.I.R. cohort (see Table S1). The median age when diabetes was ascertained was 58 (IQR: 49, 65) y. The incidence rate of diabetes was 5.88 (95% CI: 4.11, 8.41) per 1,000 person-years in the subcohort (total number of $\text{person-years} = 5,100$).

###### 

Baseline characteristics of participants in the case--cohort study nested in the D.E.S.I.R. cohort.

Table 1 lists baseline characteristics in the first column; the corresponding values of subcohort and all incident type 2 diabetes cases are listed in the other columns.

  Baseline characteristic                          Subcohort              All incident type 2 diabetes cases
  ------------------------------------------------ ---------------------- ------------------------------------
  Men                                              273 (46.7)             129 (64.2)
  Age (y)                                          47 (39, 57)            53 (45, 60)
  Education level (y)                                                     
   $< 12$                                          438 (75.6)             158 (79.0)
   $\geq 12$                                       141 (24.4)             42 (21.0)
   Missing                                         5                      1
  Marital status                                                          
   Married or living with a partner                480 (82.3)             160 (79.6)
   Single, divorced, or widowed                    103 (17.7)             41 (20.4)
   Missing                                         1                      0
  Employment                                                              
   No                                              160 (27.4)             87 (43.3)
   Yes                                             423 (72.6)             114 (56.7)
   Missing                                         1                      0
  Smoking status                                                          
   Never                                           313 (53.7)             82 (40.8)
   Former                                          169 (29.0)             61 (30.3)
   Current                                         101 (17.3)             58 (28.9)
   Missing                                         1                      0
  Physical activity                                                       
   Sedentary                                       135 (23.2)             73 (36.3)
   Moderately active                               312 (53.5)             99 (49.3)
   Active                                          136 (23.3)             29 (14.4)
   Missing                                         1                      0
  Dietary intake (kcal/d)                          1,987 (1,685, 2,503)   2,242 (1,754, 2,612)
  Family history of diabetes                       94 (16.1)              51 (25.4)
  Hypertension[^*a*^](#TF2){ref-type="table-fn"}   200 (34.2)             122 (60.7)
  Body mass index (${{kg}/m}^{2}$)                                        
   $< 25$                                          357 (61.1)             57 (28.4)
   25--29                                          188 (32.2)             85 (42.3)
   $\geq 30$                                       39 (6.7)               59 (29.3)
  Fasting blood glucose (mmol/L)                   5.25 (4.88, 5.63)      5.92 (5.52, 6.37)

Note: Data are $n$ (%) for categorical variables and median (P25, P75) for continuous variables. Percentages are based on nonmissing data. D.E.S.I.R., Data from an Epidemiological Study on the Insulin Resistance Syndrome; P, percentile.

Systolic blood pressure $\geq 140\text{ \ mmHg}$ or diastolic blood pressure $\geq 90\text{ \ mmHg}$ or ongoing blood pressure-lowering treatment.

Urinary BPA-G and BPS-G Levels {#s3.2}
------------------------------

All of the 755 participants included in the study had at least one BPA-G estimate, and 723 (96%) had two estimates. Nearly all (98%) of the 755 participants had at least one BPS-G estimate, and 606 (80%) had two estimates.

In the subcohort, the detection rate and the distribution of urinary BPA-G and BPS-G concentrations at baseline and year 3 are shown in [Table 2](#t2){ref-type="table"}. Among the 562 subcohort members with BPA data at both time points, BPA-G was detected in 403 (72%) at both visits, in 146 (26%) at only one visit, and BPA-G was not detected at either visit in 13 (2%). Within-person variability of BPA-G was high relative to total variability (ICC for log-transformed creatinine-adjusted BPA-G concentrations between the two $\text{measurements} = 0.11$) and rankings of concentrations between the two visits were weakly correlated ($\rho = 0.16$).

###### 

Urinary BPA-G, BPS-G, and creatinine concentrations at baseline and year 3 in the subcohort of the D.E.S.I.R. nested case--cohort study.

Table 2 lists particulars in the first column; the corresponding values at baseline, Year 3, and pooled baseline-Year 3 for BPA-G (nanograms per milliliter), BPS-G (nanograms per milliliter), and Creatinine (milligrams per liter) are listed in the other columns.

  Characteristic               BPA-G (ng/mL)    BPS-G (ng/mL)    Creatinine (mg/L)                                                                  
  ---------------------------- ---------------- ---------------- ------------------- ---------------- ---------------- ---------------- ----------- -----------
  Samples ($n$)                584              562              1,146               511              516              1,027            584         562
  Detection rate \[$n$ (%)\]   448 (77)         516 (92)         964 (84)            71 (14)          45 (9)           116 (11)         584 (100)   562 (100)
  Minimum                      $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$      $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$   76          98
  Percentiles (P)                                                                                                                                   
   P5                          $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$      $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$   281         387
   P25                         0.38             0.98             0.71                $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$   790         1,020
   P50                         1.46             2.12             1.75                $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$   1,220       1,444
   P75                         3.27             4.31             3.78                $< \text{LOD}$   $< \text{LOD}$   $< \text{LOD}$   1,733       1,967
   P95                         9.38             11.44            10.19               1.10             0.72             0.90             2,478       2,894
  Maximum                      75.77            67.93            75.77               84.45            439.28           439.28           6,168       4,700

Note: BPA-G, BPA-glucuronide; BPS-G, BPS-glucuronide; D.E.S.I.R., Data from an Epidemiological Study on the Insulin Resistance Syndrome; LOD, limit of detection ($0.3\text{ \ ng}/{mL}$).

Among the 455 subcohort members with BPS-G data at both time points, BPS-G was detected in 5 participants (1%) at both visits, in 95 participants (21%) at one visit, and in 355 at none of the visits (78%). The within-person stability of categories of BPS-G detection over the two visits was null (*p* for $\text{McNemar}’s\text{ \ test} = 0.03$; $\kappa = - 0.02$).

There was no difference in BPA-G concentrations according to BPS detection at the same time (*p* for $\text{Student}’s\, t\text{ \ test} = 0.73$ and 0.47 at baseline and year 3, respectively). Moreover, there was no significant crude association between urinary detection of BPA-G and BPS-G among subcohort members, at baseline (*p* for $\text{chi-square\ test} = 0.32$; $\kappa = 0.02$) or at year 3 (*p* for $\text{chi-square\ test} = 0.94$; $\kappa = - 0.06$). However, in the subcohort, the proportion of individuals with BPS-G detected at baseline and/or year 3 increased across average BPA exposure categories and was 15.8%, 19.1%, 28.0%, and 28.2% in the first, second, third, and fourth quartile groups, respectively (*p* for $\text{chi-square\ test} = 0.09$).

Associations of BPA and BPS Exposure with Incident Diabetes {#s3.3}
-----------------------------------------------------------

The associations between BPA and BPS exposure and the risk of developing diabetes are presented in [Table 3](#t3){ref-type="table"}. BPA-G concentrations at baseline were not associated with incident diabetes. However, positive associations of BPA-G concentrations at year 3 and BPA average exposure with diabetes risk were found. Compared with those in the first quartile group of average exposure, participants in the second, third, and fourth quartile groups had a near doubling of the risk of diabetes, although the association tended to be slightly reduced in the fourth quartile group: $\text{HR} = 2.56$ (95% CI: 1.16, 5.65), 2.35 (95% CI: 1.07, 5.15), and 1.56 (95% CI: 0.68, 3.55), respectively. Restricted cubic spline analysis confirmed that the risk for type 2 diabetes increased with increasing urinary BPA-G at year 3 ($p_{\text{overall}} = 0.05$) and that there was evidence for a nonlinear association ($p_{\text{nonlinearity}} = 0.01$). The graphical representation of the relationship was consistent with a nonlinear association. Indeed, [Figure 2](#f2){ref-type="fig"} shows that the HRs of type 2 diabetes increased with urine BPA-G concentration until $1.80\text{ \ ng}/{mL}$ \[$\text{HR} = 2.86$ (95% CI: 1.10, 7.44)\] and then began to decrease. In accordance with results obtained for groups of BPA exposure at baseline, we found no significant associations between urinary BPA-G at baseline and the incidence of type 2 diabetes using a restricted cubic spline model ($p_{\text{overall}} = 0.98$, $p_{\text{nonlinearity}} = 0.92$), as shown in Figure S2.

###### 

Adjusted associations between exposure to BPA and BPS and the risk of type 2 diabetes in the D.E.S.I.R. cohort (single-pollutant models).

Table 3 lists bisphenol exposure and detection in the first column. The corresponding number of type 2 diabetes cases relative to the total number of participants and adjusted hazard ratio at baseline, at year 3, and average exposure at baseline-year 3 are listed in the other columns.

  Bisphenol exposure/detections           At baseline   At year 3           Average exposure at baseline-year 3                                
  --------------------------------------- ------------- ------------------- ------------------------------------- ------------------- -------- -------------------
  BPA exposure                                          $N = 726$                                                 $N = 623$                    $N = 623$
  BPA-G concentration (ng/mL)                                                                                                                  
   $< 0.71$                               62/233        1                   11/94                                 1                   10/75    1
   0.71--1.75                             48/182        0.80 (0.53, 1.21)   28/162                                1.42 (0.66, 3.07)   33/176   2.56 (1.16, 5.65)
   1.75--3.78                             39/158        1.01 (0.65, 1.55)   44/190                                2.40 (1.16, 4.98)   36/198   2.35 (1.07, 5.15)
   $\geq 3.78$                            38/153        0.85 (0.54, 1.35)   25/177                                0.99 (0.44, 2.21)   29/174   1.56 (0.68, 3.55)
  BPS detection                                         $N = 644$                                                 $N = 579$                    $N = 529$
  BPS-G concentration $\geq \text{LOD}$                                                                                                        
   No                                     139/546       1                   92/522                                1                   61/389   1
   Yes                                    32/98         1.68 (1.09, 2.58)   15/57                                 1.92 (1.02, 3.62)   38/140   2.81 (1.74, 4.53)

Note: Groups of BPA exposure were defined on the pooled baseline and year 3 BPA-G concentrations in subcohort members. aHR, adjusted hazard ratio; BMI, body mass index; BPA-G, BPA-glucuronide; BPS-G, BPS-glucuronide; CI, confidence interval; D.E.S.I.R., Data from an Epidemiological Study on the Insulin Resistance Syndrome; LOD, limit of detection ($0.3\text{ \ ng}/{mL}$).

*n/N* indicates the numbers of type 2 diabetes cases relative to the total number of participants in each exposure category.

aHRs quantify the association between exposure to BPA/BPS and incidence of diabetes between baseline and year 9. Cox models with age as the timescale and stratified on smoking status were adjusted for sex and the following variables from baseline: urinary creatinine level, education level, employment, marital status, physical activity, caloric intake, family history of diabetes, hypertension, and BMI.

aHRs quantify the association between exposure to BPA/BPS and incidence of diabetes between year 3 and year 9. Cox models with age as the timescale and stratified on smoking status were adjusted for sex and the following variables from year 3: urinary creatinine level, education level, employment, marital status, physical activity, caloric intake, family history of diabetes, hypertension, and BMI.

aHRs quantify the association between exposure to BPA/BPS and incidence of diabetes between year 3 and year 9. Cox models with age as the timescale and stratified on smoking status were adjusted for sex, average urinary creatinine level, and the following variables from year 3: education level, employment, marital status, physical activity, caloric intake, family history of diabetes, hypertension, and BMI.

![Relationship between log-transformed BPA-G concentration at year 3 and adjusted hazard ratio (HR) of type 2 diabetes in the D.E.S.I.R. case--cohort study fitted with restricted cubic splines (three knots placed at the 10th, 50th, and 90th percentiles). Reference value for HRs is the minimum BPA-G concentration ($< \text{LOD}$); the solid line represents the HRs and the dashed lines the 95% confidence interval. $p_{\text{overall}} = 0.05$, $p_{\text{nonlinearity}} = 0.01$. Cox model with age as the timescale and stratified on smoking status was adjusted for urinary creatinine level, sex, education level, employment, marital status, physical activity, caloric intake, family history of diabetes, hypertension, and BMI (all variables from year 3). BMI, body mass index; BPA-G, bisphenol glucuronide; HR, hazard risk; D.E.S.I.R., Data from an Epidemiological Study on the Insulin Resistance Syndrome; LOD, limit of detection.](ehp-127-107013-g002){#f2}

BPS-G detection in urine at baseline was positively associated with incident diabetes \[$\text{HR} = 1.68$ (95% CI: 1.09, 2.58)\]. Considering BPS-G detection at year 3 led to similar results \[$\text{HR} = 1.92$ (95% CI: 1.02, 3.62)\]. The association between BPS and diabetes risk was stronger for the detection of BPS-G at one or both time points versus at none of the visits \[$\text{HR} = 2.81$ (95% CI: 1.74, 4.53)\]. In models including both exposures, the associations between BPS detection and diabetes risk remained of the same order of magnitude and significant after adjustment for BPA (see Table S2). The magnitude of the HRs for BPA exposure was slightly reduced when adjusted for BPS exposure.

Testing for effect--measure modification by sex revealed stronger associations between average BPS detection and diabetes risk in women \[$\text{HR} = 4.23$ (95% CI: 1.69, 10.63)\] than in men \[$\text{HR} = 1.76$ (95% CI: 0.93, 3.33), $p_{\text{interaction}} = 0.09$\] (see Table S3). There was no interaction between average BPA exposure and sex regarding the risk of diabetes. However, stronger associations were observed in women than in men. Associations of BPS exposure (at baseline and/or year 3) with incident type 2 diabetes also appeared to be modified by age, BMI, and family history of diabetes (see Table S4). BPS exposure was significantly associated with increased risk of diabetes onset in participants who were overweight or obese at baseline, in participants $< 50\text{ \ years}$ of age at baseline, and in those with a family history of diabetes (all $p_{\text{interaction}} < 0.2$). Lower and nonsignificant HR estimates were observed in normal weight participants and in participants $\geq 50\text{ \ years}$ of age. Significant but lower HR estimate was observed in those with no family history of diabetes. Because the numbers of cases became very small for these subgroup analyses, the 95% CIs were relatively wide.

Discussion {#s4}
==========

This study is one of the few prospective studies on the association between exposure to BPA and the subsequent development of type 2 diabetes and the first one on diabetes that relies on repeated urinary bisphenols measurements to assess exposure, which is crucial given the short half-life of BPA in the body. To the best of our knowledge, this is also the first study to investigate exposure to BPS in relation with the risk of developing diabetes. Our results suggest associations between diabetes risk and both BPA concentrations and BPS detection in urine, independent of traditional diabetes risk factors.

A major strength of the present study is the longitudinal design, in contrast to most of the previous epidemiological studies on BPA and diabetes, which were cross-sectional ([@c21]). Human BPA exposure occurs primarily through the diet, and reverse causality cannot be excluded in cross-sectional studies showing associations between BPA and cardiometabolic disorders. Moreover, given the strong temporal within-person variability of urinary BPA concentrations ([@c34]), a spot urine sample at the time of diabetes diagnostic is likely to be a very poor proxy of exposure in the previous years in more toxicologically relevant exposure windows. The expected consequence, assuming a classical-type error structure, corresponds to a strong attenuation bias in dose--response functions ([@c20]). Consequently, there is a need for results from prospective studies, in which BPA exposure has been assessed before the potential diabetes diagnosis, in order to better disentangle the nature of the relationship between BPA and diabetes. Our models were adjusted for total caloric intake, an important potential confounding factor rarely taken into account in previous studies ([@c21]), even though adjustment for caloric intake does not fully represent dietary intake.

In the literature, BPA levels have mostly been measured in urine because blood levels of free BPA are often not detectable in the general population ([@c28]). We studied the glucuronide metabolites of BPA and BPS as surrogates for BPA and BPS exposure. One of the advantages of studying these metabolites is to avoid contamination issues during sample collection or laboratory measurements ([@c31]). In humans, after ingestion, BPA is rapidly metabolized and almost completely excreted in urine as the glucuronide conjugate because the free form of BPA is insoluble in water ([@c32]). A study conducted in the United States showed among 31 volunteers that BPA-G was the dominant BPA form in human urine, representing 57% of the total BPA concentration, without significant differences by sex or ethnicity ([@c15]). We observed a large range of urinary BPA-G concentrations even after a 12-h fast, which is consistent with a study showing that urinary BPA levels did not decline rapidly with fasting time ([@c26]). The urinary BPA-G concentrations that we observed in the D.E.S.I.R. subcohort ($\text{median\  } = 1.46$ and $2.12\text{ \ ng}/{mL}$ at baseline and year 3, corresponding to 0.82 and $1.20\text{ \ ng}/{mL}$, respectively, BPA equivalent) are lower than those of the U.S. Nurses' Health Study II (NHSII) participants (median of urinary BPA in $\text{controls} = 2.0\text{ \ ng}/{mL}$) who provided urine samples at about the same time period (1996--2001) ([@c27]). Only limited studies have reported the occurrence of BPS in human urine, all in samples collected in the 2000s ([@c33]). Compared with most of these studies, it is likely that the detection frequency of urinary BPS is lower in our study where urine samples were collected in the 1990s, before the use of BPS had increased in consumer products. In the literature, BPS was reported to be present in human urine for the first time in 2012 and was detected in 81% of the urine samples collected from the United States and seven Asian countries, with concentrations ranging from 0.02 to $21.0\text{ \ ng}/{mL}$ and a geometric $\text{mean\  } = \, 0.17\text{ \ ng}/{mL}$ ([@c16]). In comparison, we observed that 14% of urine samples from baseline and 9% from year 3 had detectable BPS-G among subcohort members ($\text{LOD} = 0.3\text{ \ ng}/{mL}$ corresponding to $0.18\text{ \ ng}/{mL}$ BPS equivalent).

Another major strength of our study is the assessment of BPA and BPS exposure based on up to two urine samples per participant. Although this is an improved assessment over the three other prospective studies that measured BPA in only one urine sample ([@c5]; [@c25]; [@c27]), the risk of exposure misclassification remains, given the high within-person temporal variability of biomarkers such as urinary BPA-G and BPS-G. The low ICC we found for BPA-G is consistent with the results by Reeves et al. ([@c22]) and Townsend et al. ([@c29]) as part of the Nurses' Health Study (NHS) and NHSII cohorts where urinary spot samples were collected 1--3 y apart. This misclassification is expected to lead to strong loss of power and attenuation bias, by about 90% for an ICC of 0.1 ([@c20]), assuming that this 3-y period corresponds to the toxicologically relevant time period. This could explain why our results are not consistent between the two time points for BPA. Inconsistent findings were also reported in the literature, for instance, in different cycles from the National Health and Nutrition Examination Survey (NHANES) ([@c6]) or in the prospective study among U.S. women from the NHS and the NHSII cohorts ([@c27]). In order to reduce misclassification bias, we derived average BPA exposure and BPS detection using data from the two visits; exposure averaging is expected to strongly decrease bias assuming that biospecimens were collected during the right time window ([@c20]), and indeed, associations with both BPA and BPS were strengthened.

There is evidence from experimental studies that xenoestrogens, such as BPA and BPS, might have a role in the etiology of type 2 diabetes by affecting processes that are related to diabetes development, including dysfunction of pancreatic beta cells ([@c11]). Experimental studies showed that BPA exposure can affect glucose metabolism at concentrations comparable with environmental levels measured in humans from the general population ([@c17]). In humans, although several cross-sectional studies have reported positive associations between BPA and diabetes ([@c21]), findings from the few prospective studies published so far are not entirely consistent. Among women from the NHS and the NHSII cohorts, a positive and significant association between urinary BPA and incident diabetes was observed among middle-aged women from the NHSII, but there was no association in older women from the NHS ([@c27]). Among middle-aged and elderly Chinese men and women, BPA exposure was not associated with incident diabetes, but positive associations were reported with a 4-y increase in fasting blood glucose in participants with a higher diabetes genetic risk score ([@c5]). More recently, a nested case--control study conducted in employed or retired university staff in China found no association between serum BPA levels and the 5-y incidence of type 2 diabetes ([@c25]).

The present study adds to the limited literature on the prospective relationship between BPA exposure and diabetes risk and contributes to the growing body of evidence that BPA exposure may be a risk factor for diabetes independent of traditional diabetes risk factors. Our results are in favor of a nonlinear relationship between exposure to BPA and diabetes risk. Even though nonmonotonic associations could arise by chance, this finding would be consistent with the nonlinear or nonmonotonic dose--response relationships commonly described in the BPA literature, possibly related to cytotoxicity, receptor selectivity, and receptor down-regulation or competition with endogenous hormones ([@c30]) as well as mitochondrial dysfunction ([@c13]).

Another important strength of this study is its investigation of exposure to BPS, a BPA analog. Because of health concerns and regulatory actions, the use of BPA is expected to decline while the use of BPA alternatives is expected to rise, which is supported by exposure data on BPA and three bisphenol analogs from NHANES between 2000 and 2014 ([@c35]). Evidence against BPS is growing from experimental studies highlighting similar endocrine-disrupting effects to those of BPA ([@c23]). A case--control study conducted in China recently reported a cross-sectional association between urinary BPS concentrations and type 2 diabetes ([@c9]), whereas another case--control study from Saudi Arabia showed no evidence for an association between BPS and diabetes ([@c14]). To our knowledge, no prospective studies have yet considered the association between BPS exposure and the incidence of diabetes. Our findings are in favor of "low-dose" effects of BPS on diabetes risk and suggest that BPS may not be a safe alternative to BPA. However, we cannot rule out residual confounding as an explanation for these observed associations. In particular, because humans are simultaneously exposed to various chemicals that can be correlated with BPA and BPS, we cannot exclude that the associations observed were partly due to other contaminants that were not measured in this study ([@c13]). Because our urine samples were collected in the 1990s when BPS use was limited, the prevalence of BPS exposure was low in our population, and we were not able to characterize a dose--response function. Thus, the strong effect size that we report needs to be replicated in more recent cohort studies. Epidemiological studies should be encouraged to document exposure to BPA alternative compounds in order to foster discussion on the current and crucial issue of chemicals used to replace BPA and to help public authorities make informed decisions in the fields of public health and environmental policies.

Our findings suggest that the relationship of BPS exposure with type 2 diabetes may be modified by sex, age, BMI, and family history of diabetes, even though the HR estimates for these subgroup analyses were imprecise. Although no sex or BMI differences were found for the associations of BPS with type 2 diabetes in the study by Duan et al. ([@c9]), a few previous studies focusing on BPA exposure in relation to diabetes risk reported such modifying effects. For instance, our results are in line with those by Sun et al. ([@c27]) who found BPA exposure associated with the risk of type 2 diabetes among middle-aged, but not older, women. We believe these sex and age differences are biologically plausible given that BPA and BPS are known xenoestrogens that can that can interfere with the endocrine system through binding and competing for the estrogen receptors ER-alpha ($\text{ER}\alpha$), ER-beta ($\text{ER}\beta$), and estrogen-related receptor gamma ($\text{ERR-}\gamma$). The stronger associations we found among those who were overweight or obese are also consistent with the prospective study by Sun et al. ([@c27]), where urinary BPA was positively associated with type 2 diabetes risk among women with $\text{BMI} \geq 25{\,{kg}/m}^{2}$, but no significant association was found for women with $\text{BMI} < 25{\,{kg}/m}^{2}$. Last, we also hypothesized that people with a family history of type 2 diabetes may be more susceptible to the deleterious effects of environmental exposures given the associations observed between BPA exposure and increased fasting blood glucose by Bi et al. ([@c5]) in participants with a higher diabetes genetic risk score. For BPS, we detected effect modification by family history of diabetes, even though the limited statistical power led to extremely wide 95% CIs in the subgroup of individuals with family history. Overall, all the results from subgroup analyses should be interpreted with caution.

Conclusions {#s5}
===========

Our findings suggest that exposure to BPA and BPS may be associated with an increased risk for type 2 diabetes and highlight the importance of assessing the potential health hazards associated with BPA substitutes. Further research in more recent prospective cohort studies, where the BPS exposure is likely to be higher, is needed to confirm these results. Overall, caution in interpretation is needed due to the limited ability to predict long-term bisphenol exposure from spot urine samples, even repeated, and to possible residual confounding.
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